Form 4: Cytokinetics Director John T. Henderson Reports Stock Transactions
SEC Form 4 Filing
Director John T. Henderson reports acquisition and disposal of Cytokinetics Inc. common stock and acquisition of non-qualified stock options.
Summary
- On May 15, 2024, John T. Henderson, a director of Cytokinetics Inc., reported transactions involving the company's stock.
- Henderson acquired 5,600 shares of common stock at $0.
- Henderson disposed of 83 shares of common stock.
- Following these transactions, Henderson directly owns 37,670 shares of common stock.
- Henderson also indirectly owns 83 shares through a spouse.
- Henderson acquired 3,636 non-qualified stock options with an exercise price of $60.50, exercisable from June 17, 2024, and expiring on May 15, 2034.
- Following the transaction, Henderson directly owns 3,636 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, which is common in the pharmaceutical industry.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership by a director.
Key Dates
| Date | Description |
|---|---|
| 05/15/2024 | Date of stock and derivative transactions |
| 06/17/2024 | Date non-qualified stock options become exercisable |
| 05/15/2034 | Expiration date of non-qualified stock options |
| 05/16/2024 | Date of signature by attorney-in-fact |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.